
    
      In this phase II trial HLA-A2+ patients with active AML without curative treatment option are
      vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4
      times bi-weekly, then monthly.
    
  